Not just ovaries—new name for PCOS reflects the condition's multisystem nature
medicalxpress - An estimated 1 in 8 women live with polycystic ovarian syndrome, commonly referred to as PCOS. However, the name is a bit of a misnomer; it suggests that the condition affects only the ovaries. In actuality, the condition is a broader metabolic and hormon…
AI Summary: Medical experts announced a name change for polycystic ovary syndrome to better reflect its multisystem effects rather than framing it solely as an ovarian disorder. The update aims to reduce stigma, encourage holistic management of metabolic and psychological comorbidities, and align terminology with current scientific understanding of the condition.
Eli Lilly’s Triple Combo Obesity Drug Tops 28% Weight Loss in a Pivotal Trial
Frank Vinluan / medcitynews - Eli Lilly’s retatrutide set a high mark in weight loss for obesity drugs, but with clinical trial results that show some new side effects. More detailed data from the Phase 3 study are scheduled for presentation next month during the American Diabetes Ass…
AI Summary: Eli Lilly’s triple‑agonist produced average weight loss exceeding 28% in a pivotal study, positioning the drug as a leader among late‑stage obesity candidates. The results close the gap with surgical outcomes and promise major clinical and commercial impact—assuming regulators are satisfied and long‑term safety and durability data hold up.
- GLP-1 drugs closing gap with bariatric surgery (3)
- GLP-1 mechanisms and potential cancer benefits (3)
- Lilly’s retatrutide trial: 28% weight loss and implications (4)
- All Other Stories
GLP-1 drugs closing gap with bariatric surgery
GLP-1 mechanisms and potential cancer benefits
Lilly’s retatrutide trial: 28% weight loss and implications
All Other Stories
Nourish Secures $100M for Metabolic Health Clinic
Marissa Plescia / medcitynews - Nourish’s Series C round was led by Menlo Ventures, with participation from Thrive Capital, Index Ventures, J.P. Morgan Growth Equity Partners, Maverick Ventures, Y Combinator, BoxGroup, Atomico, Daybreak and Operator Partners.The post Nourish Secures $10…
AI Summary: Nourish secured a $100 million funding round to expand its virtual metabolic-health and nutrition care model, doubling down on physician integration and broader clinical rollout. The company plans to scale tele-nutrition services and deepen provider partnerships to treat metabolic disease at home, aiming to convert weight and metabolic management into reimbursable medical care.
PCOS has been officially renamed PMOS, and it’s a momentous move
newscientist - PCOS will now be known as PMOS (polyendocrine metabolic ovarian syndrome), and for Alice Klein, who has the conditon, it's been a long time coming
AI Summary: Medical experts have rebranded polycystic ovary syndrome as "polyendocrine metabolic ovarian syndrome" (PMOS) to better reflect its metabolic and endocrine drivers and improve diagnosis and treatment for about 170 million affected women worldwide. The change follows years of debate over an inaccurate name and aims to reduce misdiagnosis and guide more targeted care—because calling it something sensible might actually help.
A new Medicare option for weight loss drugs is coming: Here's what to know
Jackie Fortiér / npr - Millions of people with Medicare will soon be eligible to get discounted GLP-1 drugs for weight loss. Here's how it will work.
AI Summary: Medicare is introducing a new option to expand access to weight‑loss medications for older Americans, outlining eligibility, coverage mechanics and likely impacts on beneficiaries and budgets. The guidance aims to help clinicians and patients navigate coverage decisions and prepares stakeholders for shifts in prescribing patterns and costs as demand for GLP‑1 class drugs remains high.
- Competition, dosing and long-term weight strategies (4)
- Efficacy and safety of GLP‑1s in older adults (3)
- Medicare expansion and coverage landscape (3)
- All Other Stories
Competition, dosing and long-term weight strategies
Efficacy and safety of GLP‑1s in older adults
Medicare expansion and coverage landscape
All Other Stories
Amazon Pharmacy to offer home delivery for Novo Nordisk's Ozempic pill
fiercehealthcare - Amazon Pharmacy will make Novo Nordisk's Ozempic pill available for home delivery, the company announced Thursday.
AI Summary: Amazon Pharmacy is expanding access to Novo Nordisk’s oral semaglutide (Ozempic) by adding the pill to same‑day prescription kiosks and rolling out home delivery, widening availability beyond clinics and specialty pharmacies. Consumers will now find GLP‑1s via retail logistics — because apparently weight‑loss pills need shipping and curb‑side convenience too.
- Clinical research and future GLP-1 treatments (3)
- Payers and companies reshape access: Medicare, employers, retail programs (4)
- Retail rollout: Amazon kiosks and pharmacy delivery for Ozempic (4)
- All Other Stories
Clinical research and future GLP-1 treatments
Payers and companies reshape access: Medicare, employers, retail programs
Retail rollout: Amazon kiosks and pharmacy delivery for Ozempic
All Other Stories
CMS delays Part D GLP-1 model amid skepticism from insurers
fiercehealthcare - The Trump administration is delaying a voluntary model that aimed to expand access to GLP-1s in Part D after pushback from insurers.
AI Summary: Federal regulators have paused a Medicare Part D pilot to expand coverage for GLP‑1 weight‑loss drugs amid payer skepticism and implementation concerns. The delay reflects worries about cost, program design and insurer buy‑in, forcing policymakers to revisit the model while patients and providers wait for clarity on whether Medicare will shoulder these high‑price therapies.
- CMS pauses Medicare GLP‑1 BALANCE pilot amid insurer pushback (4)
- Researchers chase GLP‑1 benefits, from gene therapy to Alzheimer’s (6)
- Telehealth and clinics scale GLP‑1 access, delivery and monitoring (3)
- All Other Stories
CMS pauses Medicare GLP‑1 BALANCE pilot amid insurer pushback
Researchers chase GLP‑1 benefits, from gene therapy to Alzheimer’s
Telehealth and clinics scale GLP‑1 access, delivery and monitoring
All Other Stories
High-dose Wegovy debuts at $399 for self-paying patients
Paige Twenter / beckershospitalreview - Novo Nordisk’s recently approved high-dose Wegovy formulation has entered the U.S. market and is available for $399 per month for self-paying patients, the drugmaker said April 7. In March, the FDA approved Wegovy HD, a 7.2-mg injection of semaglutide, as…
AI Summary: Novo Nordisk has introduced a higher‑dose formulation of Wegovy (semaglutide) in the U.S., offering self‑pay patients access at a $399 monthly price. The rollout reflects growing demand for GLP‑1 therapies and fuels ongoing debates about affordability, access and how much of weight‑management care should depend on out‑of‑pocket spending.
- On scene: industry shifts, IPOs, stigma and miscellaneous reports (4)
- On site: Novo rolls out Wegovy HD, sparking access debates (7)
- Regulators press for more GLP-1 safety data and oversight (4)
- Reporting from clinics: GLP-1s vary in effect, risk muscle loss (9)
- All Other Stories
On scene: industry shifts, IPOs, stigma and miscellaneous reports
On site: Novo rolls out Wegovy HD, sparking access debates
Regulators press for more GLP-1 safety data and oversight
Reporting from clinics: GLP-1s vary in effect, risk muscle loss
All Other Stories
Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9B to Expand Rare Disease Portfolio
oncodaily - Neurocrine Biosciences has entered into a definitive agreement to acquire Soleno Therapeutics, marking a strategic expansion into rare disease treatments and strengthening its late-stage pipeline. The deal signals continued consolidation […]
AI Summary: Neurocrine Biosciences agreed to acquire Soleno Therapeutics for $2.9 billion, picking up Soleno’s Prader‑Willi treatment candidate and bolstering its rare‑disease portfolio. The purchase folds Soleno’s clinical assets and research teams into Neurocrine, positioning the buyer to commercialize a potential high‑value therapy while shoring up long‑term pipeline growth.
Kailera Plans IPO for Obesity Drug That Could Top Lilly’s Zepbound
Frank Vinluan / medcitynews - Kailera Therapeutics’ planned IPO will fund ongoing clinical development of a pipeline led by a drug that could rival Eli Lilly’s Zepbound in both efficacy and tolerability. Meanwhile, Renaissance Capital’s recap of first quarter 2026 IPOs shows slowing a…
AI Summary: Kailera announced plans for an initial public offering to fund late‑stage development of a Phase 3 obesity candidate licensed from Hengrui, positioning the program as a potential rival to Lilly’s Zepbound. The IPO aims to accelerate clinical work and commercial readiness as investors weigh market appetite for next‑generation weight‑loss therapies.
- Antimicrobial resistance risk found in South African wastewater (1)
- Financing rush: IPOs and venture cash fueling obesity drug race (4)
- New commercial models: subscriptions, telehealth, expanded patient access (4)
- Regulatory wins and science shaping next-generation weight-loss drugs (6)
- All Other Stories
Antimicrobial resistance risk found in South African wastewater
Financing rush: IPOs and venture cash fueling obesity drug race
New commercial models: subscriptions, telehealth, expanded patient access
Regulatory wins and science shaping next-generation weight-loss drugs
All Other Stories
Updated: Lilly’s triple-G comparable with Mounjaro, first Phase 3 diabetes data suggest
Elizabeth Cairns / endpoints - Eli Lilly’s so-called triple-G reduced blood sugar levels in patients with type 2 diabetes by up to 1.9% in a late-stage trial — a similar margin as Mounjaro achieved in its pivotal diabetes study. The triple-G ...
AI Summary: Eli Lilly’s third‑generation GLP‑1 candidate reported Phase 3 data demonstrating significant weight loss and A1C reductions, with efficacy appearing comparable to existing therapies like Mounjaro. The results sharpen competition in the GLP‑1 market and raise questions about pricing, access and who gets first dibs on the next blockbuster injection.
- At clinics: GLP‑1 demand reshaping access, care and pricing (5)
- In labs: oral pills and novel GLP‑1 delivery approaches (4)
- On the ground: Lilly's triple‑G rivaling Mounjaro in trials (3)
- Other: clinical oddities, surgical implications and pipeline setbacks (5)
At clinics: GLP‑1 demand reshaping access, care and pricing
In labs: oral pills and novel GLP‑1 delivery approaches
On the ground: Lilly's triple‑G rivaling Mounjaro in trials
Other: clinical oddities, surgical implications and pipeline setbacks
‘They Need Each Other’: Why Hims & Hers and Novo Nordisk Made Up
Marissa Plescia / medcitynews - Novo Nordisk dropped its lawsuit against Hims & Hers and launched a new collaboration. The deal is advantageous for both companies, experts say.The post ‘They Need Each Other’: Why Hims & Hers and Novo Nordisk Made Up appeared first on MedCity News.
AI Summary: Novo Nordisk has dropped its legal fight with Hims & Hers and struck a business-friendly truce: Hims will sell Novo’s branded weight‑loss medications on its platform. The abrupt move turns courtroom theatrics into commercial collaboration, smoothing distribution while leaving regulators and competitors to enjoy the schadenfreude.
Eli Lilly's new program aims to boost employer coverage of GLP-1s
Shelby Livingston / endpoints - With insurance coverage of weight loss medications stalled, Eli Lilly has developed a program to give employers another way to pay for their workers' GLP-1 treatments. The pharma giant on Thursday announced the launch of ...
AI Summary: Eli Lilly unveiled an Employer Connect program designed to help employers expand coverage for GLP‑1–class weight‑loss drugs amid stalled insurer uptake. The initiative offers new contracting and access pathways for workplaces, addressing demand while prompting debate over whether it changes the underlying benefit‑design economics. It’s helpful—if you don’t expect a revolution.
GLP‑1 drugs may fight addiction across every major substance, according to a study of 600,000 people
medicalxpress - A patient of mine, a veteran who had tried to quit smoking for over a decade, told me that after he started a GLP-1 drug for his diabetes, he lost interest in cigarettes. He didn't use a patch. He didn't set a quit date. He simply lost interest. It happen…
AI Summary: A large observational analysis suggests GLP‑1 receptor agonists — the headline-grabbing diabetes and weight-loss drugs — are linked to reduced risk of developing and dying from substance use disorders across multiple substances. Researchers urge cautious optimism: signals are intriguing, but causality remains unproven and more controlled trials are needed before rewriting addiction treatment playbooks.
Novo Nordisk inks $2.1B oral obesity drug deal
Ella Jeffries / beckershospitalreview - Novo Nordisk has partnered with Vivtex Corp. to develop next-generation oral biologic medicines for obesity, diabetes and related conditions. Under the agreement, Vivtex will license its proprietary oral drug-delivery technologies to Novo Nordisk and is e…
AI Summary: Novo Nordisk has struck a multibillion‑dollar deal with Vivtex to develop next‑generation oral biologic therapies for obesity and related metabolic diseases. The partnership funnels major R&D resources into oral delivery technology, signaling the company’s bet that pills — not injections — will be the next commercial battleground in weight‑loss medicine.
Novo Nordisk’s CagriSema beaten by Lilly’s Zepbound in head-to-head obesity trial
Elizabeth Cairns / endpoints - Novo Nordisk’s GLP-1/amylin combo drug CagriSema was not as good as Eli Lilly’s marketed obesity shot Zepbound in a head-to-head study, the Danish company said Monday. Patients in the REDEFINE 4 ...
AI Summary: In a direct comparator study, Eli Lilly’s marketed obesity drug Zepbound produced greater mean weight loss than Novo Nordisk’s experimental CagriSema. The result complicates the competitive landscape for anti‑obesity medicines and will influence prescribers, payers and the almighty market share tussle.
Intermittent fasting probably doesn’t help with weight loss
newscientist - Intermittent fasting appears to be no better than doing nothing when it comes to helping people who are overweight or have obesity lose weight
AI Summary: Large-scale reviews and new analyses find intermittent‑fasting regimens deliver weight‑loss results comparable to standard dietary advice or doing nothing special. The evidence undercuts the popular hype: fasting patterns don’t reliably outperform conventional approaches, and benefits often reflect overall calorie reduction rather than any magic timing effect.
Lilly appeals retatrutide classification ruling in case that could impact compounders
Alexis Kramer / endpoints - Eli Lilly is challenging a decision over how the FDA classified its experimental, next-gen obesity shot, in a case that could affect the ability of compounders to rival it. On Thursday, Lilly filed a notice ...
AI Summary: Eli Lilly is contesting a regulatory classification decision for its next‑generation obesity shot while simultaneously stockpiling doses ahead of potential U.S. approval. The dispute has broader implications for compounding pharmacies and has coincided with lawsuits accusing telehealth vendors and compounders of selling unapproved oral GLP‑1 alternatives — a messy intersection of commerce, regulation and patient safety.
Novo Nordisk vows legal action to protect Wegovy pill
medicalxpress - Novo Nordisk said Thursday it would take legal action against a US chain offering a copycat of the new pill version of its Wegovy weight-loss drug.
AI Summary: Novo Nordisk has vowed to take legal action after discovering that competitors – including Hims & Hers – plan to market a compounded, lower‐priced version of its new Wegovy weight‐loss pill. The company is mobilizing its legal team to protect its intellectual property amid fierce market competition.
Why doing a mix of exercise could be the key to longer life
bbc - Don't just focus on one activity - doing a variety every week gives you more health benefits, a study suggests.
AI Summary: Recent research highlights that combining different types of physical activity – rather than sticking with just one – is associated with longer life and improved health. Experts suggest that cross-training may offer cumulative benefits that help maintain overall fitness and reduce risks linked to a sedentary lifestyle.